RecruitingPhase 1NCT06121843

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Enrollment

147 participants

Start Date

Feb 22, 2024

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a CAR-T cell therapy called arlocabtagene autoleucel (BMS-986393) — where a patient's immune cells are modified in the lab to attack myeloma cells — works safely and effectively when combined with other drugs for people with multiple myeloma that has returned or stopped responding to prior treatments. **You may be eligible if...** - You have multiple myeloma that has relapsed or stopped responding to prior treatment - For Part 1: you must have received at least 3 prior treatment regimens - For Part 2: you must have received 1–3 prior treatment regimens - You are in good overall health (ECOG 0 or 1) with measurable disease **You may NOT be eligible if...** - You have previously been treated with alnuctamab, mezigdomide, iberdomide, or elranatamab (depending on the treatment arm) - You have received prior therapy targeting the GPRC5D protein - You have received prior BCMA-targeting therapy (for some treatment arms) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.